Treatment options for neuropathic pain have limited efficacy and use is fraught with dose-limiting adverse
effects. The endocannabinoid system has been elucidated over
the last several years, demonstrating a significant interface
with pain homeostasis. Exogenous cannabinoids have been
demonstrated to be effective in a range of experimental neuropathic pain models, and there is mounting evidence for
therapeutic use in human neuropathic pain conditions. This
article reviews the history, pharmacologic development, clinical trials results, and the future potential of nonsmoked, orally
bioavailable, nonpsychoactive cannabinoids in the management of neuropathic pain.